The results of a phase 4 randomized controlled trial indicate shortened regimens of preventive tuberculosis (TB) therapy are safe and effective options for preventing active TB infections, US and Brazilian researchers reported yesterday in PLOS Medicine.

The trial, conducted in Rio de Janeiro and Manaus, assigned 500 people age 15 and older without HIV who had household or occupational exposure to individuals with confirmed TB infection to receive either one or three months of isoniazid and rifapentine (HP; 1HP or 3HP). 

Both regimens have been found in previous trials to be effective at preventing active TB infection and are significantly shorter than the standard regimen (six to nine months of isoniazid), which has been the mainstay of TB preventive therapy (TPT) for decades but has had "abysmal" uptake and poor completion rates. But some data gaps remain.

"The availability of two innovative short-course TPT regimens offers a transformative opportunity for global tuberculosis control and achieving the End TB targets," the study authors wrote. "However, the safety of the 1HP regimen in people without HIV infection has not been thoroughly evaluated, and the relative acceptability of 1HP versus 3HP is unknown."

High completion rates in both groups

The primary outcomes of the trial were successful completion of more than 90% of medication in the regimens and safety.

Both treatment regimens had high completion rates—89.6% in 1HP recipients and 84.1% in the 3HP group. Adverse reactions were mostly mild or moderate, with targeted safety events or treatment discontinuation because of side effects occurring in 16.1% of patients in the 1HP group and 10.4% in the 3HP arm. Neither regimen was considered superior to the other.

The study authors say the results provide clinicians, public health officials, and patients with the data needed to make informed choices about which regimens to use and could help Brazil and other high TB-burden countries achieve TB control. 

“Preventing TB with short courses of well-tolerated medicines ensures that millions more people around the world can be protected from the devastating consequences of TB disease,” coauthor Marcelo Cordeiro-Santos, MD, PhD, said in a journal press release.

Hong Kong’s Centre for Health Protection (CHP) yesterday reported two new H9N2 avian flu cases with symptom onsets in December and January, and an H10N3 patient whose illness began on December 29. 

The H9N2 cases include a 2-year-old boy from Hunan province who got sick on December 29, and a 73-year-old woman from Guangdong province whose symptoms began in January 17. The influenza A(H10N3) case occurred in a 34-year-old man also from Guangdong province. 

None of the case-patient died from their infection, but no details were given on where they contracted the virus, symptoms, or recovery timeline. 

Inconsistencies with WHO data

CHP’s avian flu postings and reports have been inconsistent with updates from the World Health Organization (WHO), which reported three H9N2 cases from January 9 to 15, all of whom had symptom onset in November and December of last year. According to the WHO, the last known case of H10N3 was in April 2025, and the most recent case reported by the CHP would be the seventh ever reported. 

Per the CHP, there have been 20 H9N2 cases reported in China in the past 6 months.

In 2025, there were 29 H9N2 cases reported from mainland China. In 2024, the country reported 11 total cases.

The Trump administration is moving to rescind $600 million in federal health funding in four Democrat-led states—California, Colorado, Illinois, and Minnesota—with potentially far-reaching consequences for infectious-disease prevention, including HIV and other sexually transmitted disease (STD), according to media reports. 

“Reports that the Administration intends to slash hundreds of millions of dollars in Centers for Disease Control and Prevention [CDC] funding, including programs supporting HIV and STD prevention and HIV surveillance, are deeply troubling,” Anna K. Person, MD, chair of the HIV Medicine Association said in a press release emailed to reporters. 

Person notes that many grants under scrutiny expand access to HIV pre-exposure prophylaxis, “one of the most effective tools we have to prevent HIV and a strategy the Administration itself has identified as central to ending the HIV epidemic.”

Some of the funds, which Congress had already appropriated for use by state and local public health departments, are earmarked for programs that support the needs of specific communities, such as HIV prevention among Black women and Latino and African American men men who have sex with men. Last fall, the CDC revised its stated priorities, including a shift away from diseases that affect specific populations.  

Minnesota officials not yet notified of cuts

In Minnesota, officials said they have not yet received formal notice about specific funding changes.

“The Minnesota Department of Health (MDH) has yet to receive any direct communication this week from the federal government on the status of grant funding,” said Andrea Ahneman, MA, MPH, spokesperson for the MDH. “We are certainly concerned about the impact that potential cuts to federal funding could have on the health of Minnesotans and the state’s public health infrastructure.” 

Person urged the administration to withdraw the proposed rescissions and called on Congress to protect programs vital to disease prevention, adding that “the health of our communities depends on it.”